HCW Biologics is trading at $1.36, up 10.6%, with no clear reason identified for the pre-market gain. - No HCW Biologics-specific announcement for October 16 was found. - The latest company release, dated October 9, said its IND application for a solid-tumor candidate remained on track for filing in the first half of 2027; it does not establish a direct catalyst for this move. - Supplied market indicators are mixed and show no broad move exceeding 0.5% in the same direction.